Crossing the global health care quality chasm: a key component of universal health coverage

31 August 2018 - Despite years of investment and research, the quality of health care in every country is much ...

Read more →

PTAC recommended the listing of Perjeta (pertuzumab) for patients with metastatic breast cancer

At its meeting on 13-14 February 2014, the Committee reviewed an application from Roche for the funding of pertuzumab (Perjeta) ...

Read more →

NICE issues final draft guidance recommending enzalutamide for prostate cancer

People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the ...

Read more →

Clovis Oncology receives breakthrough therapy designation for CO-1686 for the second-line treatment of EGFR mutant non small-cell lung cancer in patients with the T790M mutation

Clovis Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 ...

Read more →